OMDA
VENTE TOTALE: 56 086 titres (~1 264 101,11 $ US)
- Insiders
- Duffy Sean P.
- Total bought
- —
- Total sold
- $1,264,101
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bullish signal Scored 2026-09-07
OMDA presents a compelling event-driven setup supported by strong Q2 2026 earnings momentum (43% revenue growth, EPS beat), institutional accumulation from BlackRock, and a favorable analyst price target of $26.50, all…
The first sentence of the analysis written for OMDA on 2026-09-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.7% | 60.6% | 57.0% | 48.0% | |
| Ebit Margin | -3.9% | -25.1% | -51.2% | -76.6% | |
| Ebitda Margin | -1.8% | -22.3% | -47.5% | -71.7% | |
| Operating Profit Margin | -4.6% | -25.7% | -53.8% | -81.1% | |
| Pretax Profit Margin | -4.9% | -27.8% | -55.0% | -81.3% | |
| Continuous Operations Profit Margin | -4.9% | -27.8% | -55.0% | -81.3% | |
| Net Profit Margin | -4.9% | -27.8% | -55.0% | -81.3% | |
| Bottom Line Profit Margin | -4.9% | -27.8% | -55.0% | -81.3% | |
| Current Ratio | 3.604 | 2.096 | 3.263 | 5.463 | |
| Quick Ratio | 3.545 | 2.034 | 3.180 | 5.361 | |
| Solvency Ratio | -0.096 | -0.491 | -0.828 | -1.030 | |
| Cash Ratio | 2.932 | 1.416 | 2.641 | 4.871 | |
| Price To Earnings Ratio | -71.727 | -27.059 | -19.008 | -17.692 | |
| Price To Earnings Growth Ratio | 0.968 | 0.909 | 2.746 | 0.000 | |
| Forward Price To Earnings Growth Ratio | 0.968 | 0.909 | 2.746 | 0.000 | |
| Price To Earnings Diluted Ratio | -71.727 | -27.059 | -19.008 | -17.692 | |
| Price To Earnings Diluted Growth Ratio | 0.968 | 0.909 | 2.746 | 0.000 | |
| Price To Book Ratio | 4.014 | 19.838 | 12.961 | 8.240 | |
| Price To Sales Ratio | 3.543 | 7.551 | 10.442 | 14.376 | |
| Price To Free Cash Flow Ratio | 54.460 | -33.703 | -24.348 | -17.881 | |
| Price To Operating Cash Flow Ratio | 50.516 | -37.512 | -25.777 | -18.587 | |
| Debt To Assets Ratio | 0.000 | 0.200 | 0.175 | 0.139 | |
| Debt To Equity Ratio | 0.000 | 0.467 | 0.309 | 0.198 | |
| Debt To Capital Ratio | 0.000 | 0.318 | 0.236 | 0.165 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.315 | 0.229 | 0.157 | |
| Financial Leverage Ratio | 1.330 | 2.335 | 1.770 | 1.425 | |
| Working Capital Turnover Ratio | 2.030 | 2.147 | 0.970 | 0.000 | |
| Operating Cash Flow Ratio | 0.241 | -0.633 | -1.136 | -1.999 | |
| Operating Cash Flow Sales Ratio | 0.070 | -0.201 | -0.405 | -0.773 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.928 | 1.113 | 1.059 | 1.039 | |
| Debt Service Coverage Ratio | -1.876 | -8.395 | -12.403 | -15.231 | |
| Interest Coverage Ratio | -4.725 | -9.688 | -14.027 | -17.222 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | -1.132 | -1.626 | -2.239 | |
| Capital Expenditure Coverage Ratio | 13.806 | -8.848 | -17.028 | -25.351 | |
| Dividend Paid And Capex Coverage Ratio | 13.806 | -8.848 | -17.028 | -25.351 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -147.270 | -32.672 | -20.512 | -17.892 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 65.7% | ▲5.1% | ▲7.9% |
| Ebit Margin | -3.9% | ▲21.2% | ▲35.3% |
| Ebitda Margin | -1.8% | ▲20.4% | ▲34.0% |
| Operating Profit Margin | -4.6% | ▲21.1% | ▲36.7% |
| Pretax Profit Margin | -4.9% | ▲22.9% | ▲37.3% |
| Continuous Operations Profit Margin | -4.9% | ▲22.9% | ▲37.3% |
| Net Profit Margin | -4.9% | ▲22.9% | ▲37.3% |
| Bottom Line Profit Margin | -4.9% | ▲22.9% | ▲37.3% |
| Current Ratio | 3.604 | ▲1.509 | ▼-0.002 |
| Quick Ratio | 3.545 | ▲1.511 | ▲0.015 |
| Solvency Ratio | -0.096 | ▲0.395 | ▲0.515 |
| Cash Ratio | 2.932 | ▲1.516 | ▼-0.033 |
| Price To Earnings Ratio | -71.727 | ▼-44.668 | ▼-37.856 |
| Price To Earnings Growth Ratio | 0.968 | ▲0.058 | ▼-0.188 |
| Forward Price To Earnings Growth Ratio | 0.968 | ▲0.058 | ▼-0.188 |
| Price To Earnings Diluted Ratio | -71.727 | ▼-44.668 | ▼-37.856 |
| Price To Earnings Diluted Growth Ratio | 0.968 | ▲0.058 | ▼-0.188 |
| Price To Book Ratio | 4.014 | ▼-15.823 | ▼-7.249 |
| Price To Sales Ratio | 3.543 | ▼-4.007 | ▼-5.435 |
| Price To Free Cash Flow Ratio | 54.460 | ▲88.163 | ▲59.828 |
| Price To Operating Cash Flow Ratio | 50.516 | ▲88.028 | ▲58.356 |
| Debt To Assets Ratio | 0.000 | ▼-0.200 | ▼-0.128 |
| Debt To Equity Ratio | 0.000 | ▼-0.467 | ▼-0.243 |
| Debt To Capital Ratio | 0.000 | ▼-0.318 | ▼-0.180 |
| Long Term Debt To Capital Ratio | 0.000 | ▼-0.315 | ▼-0.175 |
| Financial Leverage Ratio | 1.330 | ▼-1.005 | ▼-0.385 |
| Working Capital Turnover Ratio | 2.030 | ▼-0.116 | ▲0.744 |
| Operating Cash Flow Ratio | 0.241 | ▲0.875 | ▲1.123 |
| Operating Cash Flow Sales Ratio | 0.070 | ▲0.271 | ▲0.398 |
| Free Cash Flow Operating Cash Flow Ratio | 0.928 | ▼-0.185 | ▼-0.107 |
| Debt Service Coverage Ratio | -1.876 | ▲6.519 | ▲7.601 |
| Interest Coverage Ratio | -4.724 | ▲4.963 | ▲6.691 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | ▲1.132 | ▲1.249 |
| Capital Expenditure Coverage Ratio | 13.806 | ▲22.654 | ▲23.161 |
| Dividend Paid And Capex Coverage Ratio | 13.806 | ▲22.654 | ▲23.161 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -147.270 | ▼-114.598 | ▼-92.683 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Market cap | $922.0M | $1.28B | $1.28B | $1.28B | |
| Enterprise value | $700.0M | $1.24B | $1.20B | $1.14B | |
| EV / Sales | 2.69x | 7.28x | 9.75x | 12.84x | |
| EV / Op. cash flow | 38.35x | -36.16x | -24.07x | -16.60x | |
| EV / Free cash flow | 41.34x | -32.49x | -22.73x | -15.97x | |
| EV / EBITDA | -147.27x | -32.67x | -20.51x | -17.89x | |
| Net debt / EBITDA | 46.72x | 1.22x | 1.46x | 2.15x | |
| Current ratio | 3.60x | 2.10x | 3.26x | 5.46x | |
| Income quality | -1.43x | 0.72x | 0.74x | 0.95x | |
| Graham net-net | $3 | $0 | $1 | $2 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 124.7% | 110.6% | 107.5% | 106.1% | |
| Working capital | $197.2M | $59.1M | $99.1M | $154.0M | |
| Invested capital | $220.8M | $82.7M | $124.2M | $181.7M | |
| Return on assets | -4.2% | -31.2% | -38.6% | -32.7% | |
| Operating ROA | -5.2% | -26.8% | -33.3% | 0.0% | |
| Return on tangible assets | -4.4% | -35.3% | -43.4% | -36.2% | |
| Return on equity | -5.6% | -72.9% | -68.2% | -46.6% | |
| Return on invested capital | -5.2% | -44.8% | -50.0% | -38.5% | |
| Return on capital employed | -5.2% | -45.0% | -50.3% | -38.6% | |
| Earnings yield | -1.4% | -3.7% | -5.3% | -5.7% | |
| Free cash flow yield | 1.8% | -3.0% | -4.1% | -5.6% | |
| Capex / Op. cash flow | 7.2% | -11.3% | -5.9% | -3.9% | |
| Capex / Depreciation | 24.1% | 80.4% | 65.7% | 62.8% | |
| Capex / Sales | 0.5% | 2.3% | 2.4% | 3.1% | |
| SG&A / Sales | 54.7% | 65.1% | 83.3% | 99.8% | |
| R&D / Sales | 15.6% | 21.2% | 27.5% | 29.3% | |
| Stock comp / Sales | 5.0% | 5.5% | 7.1% | 7.5% | |
| Intangibles / Total assets | 5.1% | 11.6% | 11.1% | 9.7% | |
| Days sales outstanding | 49d | 51d | 49d | 48d | |
| Days payables outstanding | 42d | 23d | 25d | 32d | |
| Operating cycle | 67d | 69d | 74d | 76d | |
| Cash conversion cycle | 25d | 47d | 49d | 43d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-28.1%EV / Sales ▼-63.0%EV / EBITDA ▼-350.8%EV / Op. cash flow ▲+74.511Earnings yield ▲+0.023
Profitability
Return on equity ▲+0.674Return on assets ▲+0.271Return on invested capital ▲+0.396Return on capital employed ▲+0.398Operating ROA ▲+0.215Income quality ▼-2.153Tax burden 0.000
Efficiency
Days sales outstanding ▼-2.903Days payables outstanding ▲+19.283Operating cycle ▼-2.538Cash conversion cycle ▼-21.821Capex / Sales ▼-0.018R&D / Sales ▼-0.055
Balance-sheet strength
Current ratio ▲+1.509Net debt / EBITDA ▲+45.493Working capital ▲+138102000.000Invested capital ▲+138123000.000Intangibles / Total assets ▼-0.065
Change over 5 years
Valuation
Market cap ▼-28.1%EV / Sales ▼-79.0%EV / EBITDA ▼-723.1%EV / Op. cash flow ▲+54.947Earnings yield ▲+0.043
Profitability
Return on equity ▲+0.410Return on assets ▲+0.285Return on invested capital ▲+0.333Return on capital employed ▲+0.334Operating ROA n/aIncome quality ▼-2.380Tax burden 0.000
Efficiency
Days sales outstanding ▲+0.764Days payables outstanding ▲+9.704Operating cycle ▼-8.745Cash conversion cycle ▼-18.448Capex / Sales ▼-0.025R&D / Sales ▼-0.137
Balance-sheet strength
Current ratio ▼-1.859Net debt / EBITDA ▲+44.569Working capital ▲+43165000.000Invested capital ▲+39145000.000Intangibles / Total assets ▼-0.046
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-03 Omada Health, Inc. (NASDAQ:OMDA) Receives $26.50 Average PT from Brokerages Shares of Omada Health, Inc. (NASDAQ: OMDA - Get Free Report) have been given an average rating of "Moderate Buy" by the fourteen analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have issued a buy recommendation
- 2026-09-01 2,222,074 Shares in Omada Health, Inc. $OMDA Bought by BlackRock Inc. BlackRock Inc. bought a new position in shares of Omada Health, Inc. (NASDAQ: OMDA) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,222,074 shares of the company''s stock, valued at approximately $48,775,000. BlackRock Inc. owned approximately 3.74%
- 2026-08-12 Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings Omada Health (OMDA) delivered strong Q2 results, with 43% revenue growth, margin expansion, and positive adj. EBITDA, reinforcing my buy rating. OMDA''s product expansion, especially in diabetes and hypertension, is driving higher revenue per member and improving customer-lifetime-value through multi-program adoption. Channel partnerships with PBMs and health plans are lowering CAC, supporting scalable growth and better unit economics, while AI initiatives further enhance operational leverage.
- 2026-08-11 Omada Health Touts Record Q2 as GLP-1 Demand Fuels Growth Strategy Omada Health NASDAQ: OMDA highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic conditions, deepen channel partnerships and use GLP-1-related demand to broaden customer relationships.
- 2026-08-07 Omada Health, Inc. (OMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Omada Health, Inc. (OMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-08-07 Omada Health, Inc. (OMDA) Q2 2026 Earnings Call Transcript Omada Health, Inc. (OMDA) Q2 2026 Earnings Call Transcript
- 2026-08-07 Omada Health Q2 Earnings Call Highlights Omada Health NASDAQ: OMDA reported record second-quarter results for 2026, citing broad-based growth across its cardiometabolic programs, expanding channel partnerships and lower costs to serve members. The company also announced that President Wei-Li Shao will succeed Co-founder and Chief Executive Officer Sean Duffy as CEO on Jan. 1, 2027.
- 2026-08-06 Omada Health, Inc. (OMDA) Q2 Earnings and Revenues Top Estimates Omada Health, Inc. (OMDA) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to a loss of $0.09 per share a year ago.
- 2026-08-06 Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition Revenue Grew 43% and Total Members Increased 45% Year over Year, with Gross Margin Reaching a New Quarterly Record Company Announces Sean Duffy to Become Executive Chair and Wei-Li Shao to Become Chief Executive Officer on January 1, 2027 SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2026. Omada Health also announced co-founder and CEO Sean Duffy will transition to Founder and Executive Chair effective January 1, 2027, with President Wei-Li Shao assuming the role of CEO.
- 2026-07-23 UPDATE - Omada Health to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 6, 2026 SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2026 results on Thursday, August 6, 2026, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com.